✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Clinical Reference

Side Effects

Released: Last reviewed:

Most common: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%). Mostly mild-moderate and titration-dependent. Serious adverse events were uncommon but more frequent than with placebo in STEP-1.

Clinical referencePubMed-linked
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Overview

Most common: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%). Mostly mild-moderate and titration-dependent. Serious adverse events were uncommon but more frequent than with placebo in STEP-1.

PubMed citations

Related clinical pages

Key facts, checked November 20, 2026

The Wegovy label lists a boxed warning about thyroid C-cell tumors in rodents and warnings for pancreatitis, gallbladder disease, low blood sugar, kidney injury, allergic reactions, diabetic eye complications, faster heart rate and suicidal thoughts. The Wegovy label lists nausea, diarrhea, vomiting, constipation and abdominal pain among its most common adverse reactions (5% or more of patients); the label raises the dose in steps every four weeks. FDA’s November 9, 2026 safety communication adds a possible increased risk of NAION, a sudden, painless loss of vision in one eye, to every approved GLP-1 label. Report severe stomach pain, signs of gallbladder trouble or any sudden vision change to a clinician promptly.